Literature DB >> 8900854

Sweet's syndrome in a patient with idiopathic myelofibrosis and thymoma-myasthenia gravis-immunodeficiency complex: efficacy of treatment with etretinate.

G Altomare1, G L Capella, E Frigerio.   

Abstract

Here we present the case of a patient affected with a unique association of Sweet's syndrome, idiopathic myelofibrosis, spindle-cell thymoma, myasthenia gravis and Good's syndrome (a rare form of thymoma-related, combined immunodeficiency presenting with recurrent respiratory infections). Conventional therapies (corticosteroids, colchicine, DDS, clofazimine) were ineffective or were contraindicated. Treatment with etretinate (50 mg/day) proved effective on skin lesions. Moreover, the patient's general condition unexpectedly improved, with long-lasting (11 months) suppression of respiratory infections and a slight but consistent improvement of hematological parameters such as Hct, MCV, Hb level, RBC, WBC and lymphocyte absolute counts.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8900854

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  9 in total

Review 1.  Good's syndrome remains a mystery after 55 years: A systematic review of the scientific evidence.

Authors:  Theodoros Kelesidis; Otto Yang
Journal:  Clin Immunol       Date:  2010-02-10       Impact factor: 3.969

2.  Dramatic remission of anemia after thymectomy in a patient of idiopathic myelofibrosis with thymoma.

Authors:  Ying-Yih Shih; Liang-Tsai Hsiao; Ching-Fen Yang; Yu-Chung Wu; Tzeon-Jye Chiou
Journal:  Int J Hematol       Date:  2007-12-06       Impact factor: 2.490

3.  Good's syndrome and IgA monoclonal gammopathy of undetermined significance.

Authors:  Erwan Oehler; Laurence Heuberger; Frédéric Ghawche; Florent Valour
Journal:  BMJ Case Rep       Date:  2012-11-27

4.  Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.

Authors:  Tariq I Mughal; Kris Vaddi; Nicholas J Sarlis; Srdan Verstovsek
Journal:  Int J Gen Med       Date:  2014-01-29

5.  Sweet's syndrome with idiopathic thrombocythemia.

Authors:  Sebastian Kaszewski; Rafał Czajkowski; Franciszka Protas-Drozd; Waldemar Placek; Sebastian Jakubowski
Journal:  Postepy Dermatol Alergol       Date:  2014-02-25       Impact factor: 1.837

6.  Recurrent Subcutaneous Sweet's Disease in a Myelofibrosis Patient Treated with Ruxolitinib before Allogeneic Stem Cell Transplantation.

Authors:  Teppei Sakoda; Yoko Kanamitsu; Yasuo Mori; Kensuke Sasaki; Etsuko Yonemitsu; Konosuke Nagae; Goichi Yoshimoto; Kenjiro Kamezaki; Koji Kato; Katsuto Takenaka; Toshihiro Miyamoto; Masutaka Furue; Hiromi Iwasaki; Koichi Akashi
Journal:  Intern Med       Date:  2017-08-21       Impact factor: 1.271

Review 7.  Insights Into the Pathogenesis of Sweet's Syndrome.

Authors:  Michael S Heath; Alex G Ortega-Loayza
Journal:  Front Immunol       Date:  2019-03-12       Impact factor: 7.561

8.  Myasthenia Gravis and Myeloproliferative Neoplasms - Mere Association or Paraneoplastic Neurologic Syndrome: A Mini-Review.

Authors:  Sreethish Sasi; Mouhand Mohamed; P Chitrambika; Mohamed Yassin
Journal:  Acta Biomed       Date:  2022-01-19

Review 9.  Sweet's syndrome--a comprehensive review of an acute febrile neutrophilic dermatosis.

Authors:  Philip R Cohen
Journal:  Orphanet J Rare Dis       Date:  2007-07-26       Impact factor: 4.123

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.